<abstract xmlns="http://www.w3.org/1999/xhtml"><p> The therapeutic potential of cannabis has been known for centuries. Cannabinoids express their effects through two types of receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). Present studies indicate that cannabis-based drugs can make a positive impact in the treatment of different diseases. For many years, multiple sclerosis patients have self-medicated with illegal street cannabis to alleviate spasticity, a common and debilitating symptom that impairs quality of life. </p><p>Nabiximols is the cannabis-based medicine approved in many countries as an add-on therapy for symptom improvement in patients with spasticity who have not responded adequately to other medications. Adverse events such as dizziness, diarrhoea, fatigue, nausea, headache and somnolence occur quite frequently with nabiximols, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual uptitration. The prerequisite for the therapeutic use of cannabis in Serbia arerequires legal clarification for the use of the drug in a clinical environment </p></abstract>

The therapeutic potential of cannabis has been known for centuries. Cannabinoids express their effects through two types of receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). Present studies indicate that cannabis-based drugs can make a positive impact in the treatment of different diseases. For many years, multiple sclerosis patients have self-medicated with illegal street cannabis to alleviate spasticity, a common and debilitating symptom that impairs quality of life. Nabiximols is the cannabis-based medicine approved in many countries as an add-on therapy for symptom improvement in patients with spasticity who have not responded adequately to other medications. Adverse events such as dizziness, diarrhoea, fatigue, nausea, headache and somnolence occur quite frequently with nabiximols, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual uptitration. The prerequisite for the therapeutic use of cannabis in Serbia arerequires legal clarification for the use of the drug in a clinical environment

Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

Clinic of Neurology, Clinical Centre Kragujevac, Kragujevac, Serbia, Zmaj Jovina 30, 34 000 Kragujevac Tel: 0607129294; Fax: 034370166

Clinic for Psychiatric Illnesses “Dr Laza Lazarevic”, Belgrade, Serbia

Department of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Psychiatric Clinic, Clinical Centre Kragujevac, Kragujevac, Serbia

Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Belgrade, Belgrade, Serbia

Clinic of Neurology, Clinical Centre Kragujevac, Kragujevac, Serbia

Department of Neurology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The therapeutic potential of cannabis has been known for centuries. Cannabinoids express their effects through two types of receptors, cannabinoid receptor 1...

Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

Online veröffentlicht: 14. Apr. 2016

Seitenbereich: 61 - 66

Eingereicht: 04. März 2015

Akzeptiert: 14. Mai 2015

DOI: https://doi.org/10.1515/sjecr-2015-0047

Schlüsselwörter
cannabis, multiple sclerosis, spasticity, nabiximols

© 2016

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

Online veröffentlicht: 14. Apr. 2016

Seitenbereich: 61 - 66

Eingereicht: 04. März 2015

Akzeptiert: 14. Mai 2015

DOI: https://doi.org/10.1515/sjecr-2015-0047

Schlüsselwörtercannabis, multiple sclerosis, spasticity, nabiximols

© 2016

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Schlüsselwörter
cannabis, multiple sclerosis, spasticity, nabiximols